Novo Nordisk starts recruitment for combination trial of semaglutide and Astrazeneca tablet
The new phase I study aims to determine whether diabetes treatments semaglutide and dapagliflozin can be combined in one pill.
by mikkel aabenhus hemmingsen, translated by catherine brett
Is it possible to create a diabetes tablet which improves treatment by combining several existing products in one pill?
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
US Senators introduce bill to cap insulin prices
For subscribers
